What one share of Gain Therapeutics holds
We are a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (“CNS”) disorders, lysosomal storage disorders (“LSDs”), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology.
Gain Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.51 |
|---|---|
| Cash and investments | $0.30 |
| Debt | $0.01 |
| Book value | $0.26 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.01 | −$1.33 | $0.01 | −$1.22 | — | $1.75 |
| 2021 | $0.02 | −$1.37 | $0.01 | −$1.23 | — | $2.93 |
| 2022 | $0.01 | −$1.48 | $0.01 | −$1.25 | — | $1.59 |
| 2023 | $0.00 | −$1.71 | $0.00 | −$1.45 | — | $0.78 |
| 2024 | — | −$0.89 | $0.00 | −$0.83 | — | $0.27 |
| 2025 | — | −$0.61 | — | — | — | $0.44 |
Common questions about Gain Therapeutics
How much does one share of Gain Therapeutics earn?
Over the last 12 months, Gain Therapeutics lost $0.51 for each share.
Does Gain Therapeutics pay a dividend?
Gain Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Gain Therapeutics’s book value per share?
Gain Therapeutics’s book value is $0.26 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Gain Therapeutics have?
Each share of Gain Therapeutics has $0.30 of cash and investments and $0.01 of debt, as of June 30, 2026.
Has Gain Therapeutics bought back shares?
Gain Therapeutics’s share count rose about 1130% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.